Ad is loading...
FSCZX
Price
$30.76
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VVIAX
Price
$69.72
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

FSCZX vs VVIAX

Header iconFSCZX vs VVIAX Comparison
Open Charts FSCZX vs VVIAXBanner chart's image
Fidelity Advisor Stk Selec Lg Cp Val Z
Price$30.76
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Value Index Adm
Price$69.72
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
FSCZX vs VVIAX Comparison Chart
Loading...
View a ticker or compare two or three
VS
FSCZX vs. VVIAX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSCZX is a Buy and VVIAX is a StrongBuy.

FUNDAMENTALS
Fundamentals
VVIAX has more cash in the bank: 184B vs. FSCZX (600M). VVIAX pays higher dividends than FSCZX: VVIAX (2.36) vs FSCZX (1.22). FSCZX was incepted earlier than VVIAX: FSCZX (8 years) vs VVIAX (24 years). FSCZX is a more actively managed with annual turnover of: 70.00 vs. VVIAX (10.00). FSCZX has a lower initial minimum investment than VVIAX: FSCZX (0) vs VVIAX (3000). FSCZX (26.81) and VVIAX (26.09) have marching annual gain over last year. FSCZX (54.34) and VVIAX (53.09) have equivalent 5 years return.
FSCZXVVIAXFSCZX / VVIAX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence8 years24 years-
Gain YTD20.51419.672104%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets600M184B0%
Annual Yield % from dividends1.222.3652%
Returns for 1 year26.8126.09103%
Returns for 3 years19.5224.7779%
Returns for 5 years54.3453.09102%
Returns for 10 yearsN/A112.26-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DOLE15.260.19
+1.26%
Dole plc
NCNO40.450.37
+0.92%
nCino
SGHT3.760.03
+0.80%
Sight Sciences
VICI32.370.25
+0.78%
VICI Properties
SABS3.070.01
+0.33%
SAB Biotherapeutics